Overview Forte Biosciences, Inc. and its subsidiaries (www.fortebiorx.com) (Forte, we, our) is a clinical-stage biopharmaceutical company whose current lead product candidate is FB102. FB102 is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. Our FB102 program aims to address key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulato...
Q2 FY2026 — expected 2026-08-19
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-31 | 2025-12-31 | 0001193125-26-134498 | EDGAR | 70K words |
| 2025-03-28 | 2024-12-31 | 0000950170-25-046749 | EDGAR | — |
| 2024-03-18 | 2023-12-31 | 0000950170-24-032843 | EDGAR | — |
| 2023-03-31 | 2022-12-31 | 0000950170-23-011355 | EDGAR | — |
| 2022-03-31 | 2021-12-31 | 0001564590-22-012987 | EDGAR | — |
| 2021-03-16 | 2020-12-31 | 0001564590-21-013249 | EDGAR | — |
| 2020-02-27 | 2019-12-31 | 0001564590-20-007402 | EDGAR | — |
| 2019-02-27 | 2018-12-31 | 0001564590-19-004933 | EDGAR | — |
| 2018-03-09 | 2017-12-31 | 0001564590-18-005132 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-14 | 2025-09-30 | 0001193125-25-281808 | EDGAR | 53K words |
| 2025-08-14 | 2025-06-30 | 0000950170-25-108889 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0000950170-25-072569 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0000950170-24-127031 | EDGAR | — |
| 2024-08-14 | 2024-06-30 | 0000950170-24-096988 | EDGAR | — |
| 2024-05-13 | 2024-03-31 | 0000950170-24-058669 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0000950170-23-062907 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0000950170-23-042518 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0000950170-23-022184 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0000950170-22-024977 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0000950170-22-017378 | EDGAR | — |
| 2022-05-16 | 2022-03-31 | 0001564590-22-020257 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-04-01 | 0001193125-26-135767 | EDGAR | 2K words |
| 2025-11-14 | 0001193125-25-281807 | EDGAR | — |
| 2025-08-14 | 0001193125-25-180771 | EDGAR | — |
| 2025-06-25 | 0001193125-25-147017 | EDGAR | — |
| 2025-06-23 | 0001193125-25-144174 | EDGAR | — |
| 2025-05-30 | 0001193125-25-131525 | EDGAR | — |
| 2025-05-15 | 0001193125-25-120772 | EDGAR | — |
| 2025-04-18 | 0001193125-25-085762 | EDGAR | — |
| 2025-04-04 | 0001193125-25-073403 | EDGAR | — |
| 2025-01-24 | 0001193125-25-012236 | EDGAR | — |
162 total filings indexed. 131 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001419041 |
| Ticker | FBRX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.fortebiorx.com |
| Listed | 2020-06-16 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report